Charles River Laboratories International Inc (NYSE:CRL): Stock Big Money Like: at 1.13

June 29, 2018 - By Alberta Moore

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo

Charles River Laboratories International Inc’s Sentiment

“Big money sentiment for Charles River Laboratories International Inc (NYSE:CRL) in Q1 2018 increased to 1.13, according to SEC.gov filings. That’s up 0.05, from 2017Q4’s 1.08. 140 funds started new or increased stock positions, while 124 cut down and sold their equity positions in Charles River Laboratories International Inc so the sentiment improved. Funds own 44.28 million shares, down from 44.57 million shares in 2017Q4. Funds holding Charles River Laboratories International Inc in top 10 decreased from 2 to 1 for a decrease of 1. In total 31 funds closed positions, 93 reduced and 96 increased. Also 44 funds bought new Charles River Laboratories International Inc stakes.

Largest Charles River Laboratories International Inc Investors

Channing Capital Management Llc owns 701,583 shares in Charles River Laboratories International Inc as of Q1 2018. Charles River Laboratories International Inc’s shareholder Van Berkom & Associates Inc. owns 613,141 shares as of Q1 2018. Copper Rock Capital Partners Llc reported 301,980 shares. The Illinois-based fund Ariel Investments Llc have invested about 1.66% of the investment manager’s stock portfolio in Charles River Laboratories International Inc. The Michigan-based fund Norris Perne & French Llp Mi looks positive on Charles River Laboratories International Inc, possessing 99,543 shares.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The company has $5.40 billion market cap. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).The P/E ratio is 42.52. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

Ticker’s shares touched $112.69 during the last trading session after 1.32% change.Charles River Laboratories International, Inc. has volume of 53,270 shares. Since June 29, 2017 CRL has risen 12.87% and is uptrending. CRL outperformed the S&P500 by 0.30%.

On August, 8. Investors wait Charles River Laboratories International, Inc. (NYSE:CRL) to reveal its quarterly earnings, as reported by RTT. This year’s earnings per share analyst estimate is expected to be $1.47. That is 13.95 % up compareed to $1.29 earnings per share for last year. If reported the P/E will be 19.16 with $70.43 million profit. After $1.38 EPS report previous quarter, Wall Street now forecasts 6.52 % EPS growth of Charles River Laboratories International, Inc..

Dekabank Deutsche Girozentrale has invested 0.17% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Archford Cap Strategies Limited Company stated it has 0% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Prns Ltd Com holds 136,200 shs or 0.49% of its capital. Ing Groep Nv holds 7,214 shs. Alyeska Inv Limited Partnership holds 617,804 shs or 0.6% of its capital. Bnp Paribas Asset Holding, a France-based fund reported 144,556 shs. Gotham Asset Limited Co holds 0% or 2,750 shs. 14,538 were accumulated by Amica Mutual Insurance Com. Hood River Cap Management Ltd owns 196,887 shs. 12,739 are held by Systematic Fincl Lp. Regions Fincl accumulated 1 shs or 0% of the stock. Captrust Financial Advsrs has invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). New York-based Opus Point Mgmt Ltd Liability Corporation has invested 0.55% in Charles River Laboratories International, Inc. (NYSE:CRL). Peak6 Invests Limited Partnership, Illinois-based fund reported 12,567 shs. Shaker Investments Lc Oh has invested 0.53% in Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc. had 24 selling transactions and 0 insider buys since January 2, 2018. This’s net activity of $11.12 million. FOSTER JAMES C sold $476,046 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Wednesday, February 28. On Tuesday, March 6 Girshick Birgit sold $1.08M worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 9,893 shs. On Monday, February 26 3,868 shs were sold by Smith David Ross, worth $415,224. On Friday, March 9 $890,100 worth of stock was sold by MILNE GEORGE M JR. CHUBB STEPHEN D sold $312,172 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 2,872 shs on Thursday, February 15. Barbo William D sold $250,741 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Wednesday, February 21.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

A total of 10 analysts rate Charles River (NYSE:CRL) as follows: 5 “Buy”, 5 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NYSE:CRL) has 11 ratings reports on 29 Jun 2018 according to StockzIntelligence. In Tuesday, April 24 report Jefferies maintained the stock with “Buy” rating. On Wednesday, February 14 the stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Overweight” rating by JP Morgan. The company rating was maintained by Morgan Stanley on Wednesday, March 14. On Wednesday, February 14 SunTrust upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to “Buy” rating. On Monday, January 22 the rating was downgraded by SunTrust to “Hold”. On Friday, June 15 the stock has “Overweight” rating by KeyBanc Capital Markets. On Tuesday, February 13 the stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Buy” rating by Robert W. Baird. On Friday, April 20 the stock has “Hold” rating by MUFG Securities Americas Inc. In Tuesday, February 13 report RBC Capital Markets maintained it with “Hold” rating and $116.0 target.

For more Charles River Laboratories International, Inc. (NYSE:CRL) news released recently go to: Benzinga.com, 247Wallst.com, Benzinga.com, Benzinga.com or Businesswire.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For June 15, 2018” released on June 15, 2018, “Top Analyst Upgrades and Downgrades: Advanced Micro Devices, Delphi, Domino’s Pizza, Southwest Airlines, Square …” on June 15, 2018, “Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade” with a publish date: June 15, 2018, “The Market In 5 Minutes: Tariffs, NXPI, Powell And More” and the last “Charles River Laboratories to Present at Jefferies and William Blair Conferences” with publication date: June 04, 2018.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: